FSA Wealth Management LLC Invests $50,000 in Danaher Co. (NYSE:DHR)

FSA Wealth Management LLC purchased a new position in shares of Danaher Co. (NYSE:DHR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 180 shares of the conglomerate’s stock, valued at approximately $50,000.

Other hedge funds have also bought and sold shares of the company. HBW Advisory Services LLC acquired a new position in Danaher in the second quarter worth $216,000. Mather Group LLC. grew its position in shares of Danaher by 155.8% during the 2nd quarter. Mather Group LLC. now owns 8,182 shares of the conglomerate’s stock valued at $2,043,000 after buying an additional 4,984 shares during the last quarter. Lynx Investment Advisory acquired a new stake in Danaher during the second quarter worth about $63,000. Eastover Investment Advisors LLC lifted its holdings in Danaher by 5.0% in the second quarter. Eastover Investment Advisors LLC now owns 5,455 shares of the conglomerate’s stock worth $1,311,000 after acquiring an additional 262 shares during the last quarter. Finally, Harbor Capital Advisors Inc. boosted its stake in Danaher by 8.3% in the second quarter. Harbor Capital Advisors Inc. now owns 11,505 shares of the conglomerate’s stock valued at $2,875,000 after acquiring an additional 879 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

NYSE:DHR opened at $239.69 on Monday. Danaher Co. has a 52-week low of $215.68 and a 52-week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a market cap of $173.12 billion, a P/E ratio of 45.74, a PEG ratio of 4.41 and a beta of 0.85. The business’s 50-day moving average price is $254.59 and its 200 day moving average price is $259.41.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.02 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s payout ratio is 20.61%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DHR. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research report on Thursday, October 31st. Evercore ISI raised their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Wednesday, November 27th. Raymond James cut their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, Stephens reissued an “overweight” rating and set a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.